Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05351333 · ClinicalTrials.gov registry record · NA

Conditioning & Open-Label Placebo (COLP) for Opioid Management in Intensive Inpatient Rehabilitation

A NA study of Spinal Cord Injuries and Burns, sponsored by Spaulding Rehabilitation Hospital.

Active
Registry status
NA
Development phase
66
Enrollment target
1
Study location

NCT05351333 is a NA study of Spinal Cord Injuries and Burns that is active but no longer recruiting, run by Spaulding Rehabilitation Hospital. The registered enrollment target is 66 participants, roughly in line with the 61-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05351333, a NA study of Spinal Cord Injuries and Burns, is active but no longer recruiting, sponsored by Spaulding Rehabilitation Hospital.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
66 participants
Enrollment target
1
Study location

Study Summary

The use of the conditioning open-label placebo (COLP) paradigm will be studied as a dose extension method to lower opioid dosage in patients with spinal cord injury, polytrauma, and burn injury. The goal is to provide the same level of pain relief with a reduced opioid intake to diminish side effects as well as the risk of addiction associated with opioid treatment.

Interventions

  • OTHER placebo

Study Locations (1)

Massachusetts

  • Spaulding Rehabilitation Hospital - Charlestown

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2022-08-03
Est. Completion 2026-07-31
Phase NA

Sponsor

Spaulding Rehabilitation Hospital

101 total trials

What the Registry Record Tells You About NCT05351333

The ClinicalTrials.gov registry entry for NCT05351333 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 61-participant average among 202 other Spinal Cord Injuries trials with a reported enrollment target. The listed sponsor is Spaulding Rehabilitation Hospital, which has 101 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Spinal Cord Injuries appearing as the primary indexed condition, and to 1 intervention - of which placebo is the first listed.

NCT05351333 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05351333 about?

NCT05351333 is a clinical study titled "Conditioning & Open-Label Placebo (COLP) for Opioid Management in Intensive Inpatient Rehabilitation". The use of the conditioning open-label placebo (COLP) paradigm will be studied as a dose extension method to lower opioid dosage in patients with spinal cord injury, polytrauma, and burn injury. The goal is to provide the same level of pain relief with a reduced opioid intake to diminish side effect...

What is the current status of trial NCT05351333?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 66 participants. The study started on 2022-08-03. Estimated completion is 2026-07-31.

What conditions does trial NCT05351333 study?

This clinical trial studies the following conditions: Spinal Cord Injuries, Burns, Polytrauma.

What interventions are being tested in trial NCT05351333?

The interventions under investigation include: placebo (OTHER).

Who is sponsoring clinical trial NCT05351333?

This trial is sponsored by Spaulding Rehabilitation Hospital, which has 101 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05351333 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Spinal Cord Injuries

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.